Drug Trial Radar · NCT05220917
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
781,430
Planned (sponsor's estimate)
Start
Aug 1, 2021
Primary completion
May 31, 2026
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Brigham and Women's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Patient-Centered Outcomes Research Institute; VA Boston Healthcare System; McGill University
- First posted
- Feb 2, 2022
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To perform an observational analysis to emulate a target trial (i.e., a hypothetical pragmatic trial that would have answered the causal question of interest) comparing the effectiveness and safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide 1 receptor agonists (GLP-1RA), dipeptidyl peptidase-4 inhibitors (DPP-4i), and sulfonylureas (SU), at the class and individual agent level, in head-to-head comparisons in patients with type 2 diabetes (T2D).
Conditions
- Cardiovascular Events
- Type2 Diabetes
- Renal Disease
Interventions
SGLT2 inhibitorDrug
Any SGLT2i dispensing claim
DPP-4 inhibitorDrug
Any DPP-4 inhibitor claim
GLP-1RADrug
Any SGLT2i dispensing claim
2nd generation SUDrug
Any 2nd generation SU claim
Primary outcomes
What the sponsor says the trial is designed to measure.
- MACETime frame: through study completion, an average of 1 year
- Modified MACETime frame: through study completion, an average of 1 year
- Hospitalization for Heart Failure (HHF) Hospitalization for Heart Failure (HHF)Time frame: through study completion, an average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Brigham and Women's Hospital
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.